These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

628 related items for PubMed ID: 17713889

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW, Bickston SJ.
    Cochrane Database Syst Rev; 2008 Jan 23; (1):CD006893. PubMed ID: 18254120
    [Abstract] [Full Text] [Related]

  • 3. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors.
    Prescrire Int; 2009 Jun 23; 18(101):108-10. PubMed ID: 19637418
    [Abstract] [Full Text] [Related]

  • 4. Anti-tumor necrosis factor agents reduce corticosteroid use compared with azathioprine in patients with Crohn's disease.
    Kane SV, Jaganathan S, Bedenbaugh AV, Palmer L, Schwartz DA.
    Curr Med Res Opin; 2014 Sep 23; 30(9):1821-6. PubMed ID: 24884302
    [Abstract] [Full Text] [Related]

  • 5. Is there a benefit from the concomitant use of immunosupression with anti-TNF in Crohn's disease; heads or tails?
    Lakatos PL.
    Rev Recent Clin Trials; 2009 Sep 23; 4(3):152-8. PubMed ID: 20028325
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F, Portela F.
    BioDrugs; 2010 Dec 14; 24 Suppl 1():3-14. PubMed ID: 21175228
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.
    Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF.
    Clin Gastroenterol Hepatol; 2008 Jun 14; 6(6):644-53. PubMed ID: 18550004
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
    Danese S.
    Curr Drug Targets; 2010 Feb 14; 11(2):136-7. PubMed ID: 20214597
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.